View the CAT IPE logo printer-friendly / share this CAT
Title Mesenchymal Stem Cell Treatment (MSCT) May Alleviate Salivary Problems Associated with Sjogren's Syndrome
Clinical Question Will a middle-aged patient with Sjogren's Syndrome increase salivary flow with stem cell treatment compared to no stem cell treatment?
Clinical Bottom Line Mesenchymal stem cell treatment (MSCT) may alleviate salivary problems associated with Sjogren's Syndrome. This was shown in a clinical trial of 11 patients treated with MSCs, resulting in significantly increased salivary flow.
Best Evidence (you may view more info by clicking on the PubMed ID link)
PubMed ID Author / Year Patient Group Study type
(level of evidence)
#1) 22927248Xu/201211 primary Sjogren's Syndrome patients 27-68 years oldClinical Trial
Key results All patients showed improvements after mesenchymal stem cell therapy. Mean Sjogren's Syndrome Disease Damage Index scores decreased from 5.63 ± 1.44 (starting) to 4.58 ± 1.67 at 2 weeks, 4.33 ± 1.79 at 1 month, 4.08 ± 1.44 at 3 months, 3.46 ± 1.18 at 6 months, and 3.08 ± 1.21 at 12 months. Unstimulated salivary flow rate of all patients (n=11) with symptoms of xerostomia improved significantly (P=.0005) at 2 weeks while improving significantly for stimulated salivary flow (P=.016) at 12 months. The modified Treatment Emergent Symptom Scale score for xerostomia decreased 2 weeks after MSCT and maintained the lower level (P=.05).
Evidence Search ("stem cells"[MeSH Terms] OR ("stem"[All Fields] AND "cells"[All Fields]) OR "stem cells"[All Fields] OR ("stem"[All Fields] AND "cell"[All Fields]) OR "stem cell"[All Fields]) AND ("therapy"[Subheading] OR "therapy"[All Fields] OR "treatment"[All Fields] OR "therapeutics"[MeSH Terms] OR "therapeutics"[All Fields])
Comments on
The Evidence
Validity: This study enrolled 24 patients with Sjogren's Syndrome (23 female and 1 male) of which only 11 patients had related xerostomia symptoms. All of the patients finished the entire study, which consisted of an umbilical cord mesenchymal stem cell treatment with an adequate follow up of 12 months. There were no competing interests and compliance was adequate. The study was not a double blind study. Perspective: The patient pool is very small and not very cohesive. With only 11 patients actually receiving treatment in regards to xerostomia, there isn’t sufficient evidence to fully support the results. However, the results are all in unison even in the midst of the wide range of patient ages (27 to 68 yrs)
Applicability This research is in the initial stages of addressing a fairly current topic, providing limited credibility. However, this may be an exciting beginning to permanently treating patients with Sjogren's Syndrome, especially since there is not currently a cure for this disease.
Specialty/Discipline (Oral Medicine/Pathology/Radiology) (General Dentistry) (Basic Science)
Keywords Sjogren's Syndrome, Mesenchymal Stem Cells, Xerostomia
ID# 2834
Date of submission: 04/04/2015spacer
E-mail kangd3@livemail.uthscsa.edu
Author Jason Kang
Co-author(s) e-mail
Faculty mentor/Co-author Howard Dang, PhD
Faculty mentor/Co-author e-mail dang@uthscsa.edu
Basic Science Rationale
(Mechanisms that may account for and/or explain the clinical question, i.e. is the answer to the clinical question consistent with basic biological, physical and/or behavioral science principles, laws and research?)
post a rationale
None available
Comments and Evidence-Based Updates on the CAT
post a comment
None available

Return to Found CATs list